发明名称 |
Pharmaceutical combination of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-Glutamic acid |
摘要 |
Disclosed is the use of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2- indolinone or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for simultaneous, separate or sequential 5 use with the compound N-[4-[2-(2- amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]- L-Glutamic acid or a pharmaceutically acceptable salt thereof, in the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis, in a human or non-human mammalian body. |
申请公布号 |
NZ588957(A) |
申请公布日期 |
2013.03.28 |
申请号 |
NZ20090588957 |
申请日期 |
2009.06.04 |
申请人 |
BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
发明人 |
STEFANIC, MARTIN FRIEDRICH;HILBERG, FRANK;KAISER, ROLF;SHAPIRO, DAVID |
分类号 |
A61P9/00;A61K31/404;A61K31/496;A61K31/519;A61P1/16;A61P3/10;A61P11/06;A61P17/06;A61P19/02;A61P25/02;A61P27/02;A61P35/00;A61P43/00 |
主分类号 |
A61P9/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|